ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

@inproceedings{Sun2011ERCC1AA,
  title={ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy},
  author={Jong-mu Sun and Ji-youn Sung and Se Hoon Park and Ghee Young Kwon and Byong Chang Jeong and Seong Il Seo and Seong Soo Jeon and Hyun Moo Lee and Jisuk Jo and Han Yong Choi and Ho-yeong Lim},
  booktitle={BMC Cancer},
  year={2011}
}
The role of adjuvant chemotherapy and the value of molecular biomarkers in bladder cancer have not been determined. We aimed to assess the predictive and prognostic values of excision repair cross-complementation 1 (ERCC1) in identifying appropriate patients who may potentially benefit from adjuvant chemotherapy for bladder cancer. A retrospective analysis was performed on 93 patients with completely resected transitional cell carcinoma of the bladder. ERCC1 expression was assessed by… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Similar Papers

Loading similar papers…